GlaxoSmithKline (NYSE:GSK) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Monday, ValuEngine reports.
GSK has been the topic of several other reports. Jefferies Financial Group restated a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday. New Street Research upgraded shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Wednesday, October 16th. Societe Generale upgraded shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and three have issued a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average target price of $41.79.
Shares of GSK stock traded up $0.07 on Monday, hitting $42.60. 1,931,039 shares of the stock traded hands, compared to its average volume of 2,502,367. The firm has a market cap of $105.93 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 2.03 and a beta of 0.68. GlaxoSmithKline has a 52 week low of $36.41 and a 52 week high of $43.22. The firm has a 50 day simple moving average of $41.88 and a two-hundred day simple moving average of $40.80. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The firm had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. Sell-side analysts forecast that GlaxoSmithKline will post 2.97 EPS for the current year.
In related news, Director Plc Glaxosmithkline purchased 177,777 shares of GlaxoSmithKline stock in a transaction on Tuesday, September 10th. The shares were bought at an average cost of $45.00 per share, for a total transaction of $7,999,965.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC grew its stake in shares of GlaxoSmithKline by 7,574.0% in the 2nd quarter. Jane Street Group LLC now owns 1,816,424 shares of the pharmaceutical company’s stock worth $72,693,000 after buying an additional 1,792,754 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of GlaxoSmithKline by 6.9% in the 2nd quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock worth $610,776,000 after buying an additional 989,181 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of GlaxoSmithKline by 362.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,105,172 shares of the pharmaceutical company’s stock worth $44,229,000 after buying an additional 866,015 shares in the last quarter. Invesco Ltd. grew its stake in shares of GlaxoSmithKline by 502.4% in the 2nd quarter. Invesco Ltd. now owns 644,331 shares of the pharmaceutical company’s stock worth $25,786,000 after buying an additional 537,370 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of GlaxoSmithKline in the 2nd quarter worth $20,154,000. Institutional investors own 11.12% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: How Does the Quiet Period Work?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.